Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Completes $70M Acquisition of AbD Serotec

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.

Bio-Rad announced its intention to acquire the business in December.

AbD Serotec offers more than 15,000 antibodies, kits, and accessories. It has an ISO 9001 and ISO 13485 certified production facility in the UK and additional facilities in Germany and the US.

Norman Schwartz, Bio-Rad's president and CEO, said that the acquisition gives Bio-Rad "total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting."

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.